{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:05:37Z","timestamp":1794492337567,"version":"4.9.1"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","funder":[{"name":"National Institute of Child Health and Human Development","award":["HD047905"],"award-info":[{"award-number":["HD047905"]}]},{"name":"National Institute of Child Health and Human Development","award":["HD096796"],"award-info":[{"award-number":["HD096796"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Buprenorphine (BUP) use is prevalent in pregnant women with opioid use disorder (OUD). Drug monitoring during pregnancy is critical for optimizing dosing regimen and achieving the desired clinical outcomes. Hair can be used as a critical biological matrix for monitoring long-term exposure to drugs. The aim of this study was to optimize the methodology used to quantify BUP and its metabolites in hair samples.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Conditions for hair sample processing (ie, hair washing, incubation temperature, and extraction time) were optimized to maximize extraction recovery. The LC-MS\/MS strategy employed here used 4 deuterated internal standards for quantifying BUP and its major metabolites [norbuprenorphine (NBUP), buprenorphine glucuronide (BUP-G), and norbuprenorphine-glucuronide (NBUP-G)] in human hair samples. The optimized conditions were used to measure BUP and its metabolites in hair samples of 5 women undergoing OUD treatment and their neonates.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Unwashed hair samples processed by shaking with acetonitrile for 24 hours at 37 \u00b0C showed higher BUP (36%) and NBUP (67%) recovery, compared with those processed by incubation at room temperature. The standard curves showed excellent linearity over 0.05\u2013100 ng\/mL for BUP and NBUP and 0.1\u2013200 ng\/mL for BUP-G and NBUP-G. The assay was partially validated for reproducibility and accuracy and was successfully used for measuring BUP and metabolites in aforementioned hair samples. BUP was identified in all hair samples, while BUP-G was not. BUP was the primary analyte in maternal hair (median: 38.3 pg\/mg; 25\u201375 percentile: 17\u2013152.4 pg\/mg), while NBUP-G was predominant in neonatal hair (median: 28.6 pg\/mg; 25%\u201375% percentile: 1.9\u2013112.8 pg\/mg).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The methodology used for quantifying BUP and its metabolites in hair samples of maternal female patients and their neonates is simple, accurate, and reproducible. The developed method may be useful for measuring fetal exposure to BUP during gestation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001291","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T17:00:56Z","timestamp":1734109256000},"page":"413-420","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["An Approach for Improving the Detection and Quantitation of Buprenorphine and Its Metabolites in Maternal and Neonatal Hair"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2466-4763","authenticated-orcid":false,"given":"Osama Y.","family":"Alshogran","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania;"},{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0501-8459","authenticated-orcid":false,"given":"Wenchen","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8190-6039","authenticated-orcid":false,"given":"Elizabeth E.","family":"Krans","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynecology and Reproductive Sciences, School of Medicine, UPMC Magee-Women's Hospital;"},{"name":"Magee-Women's Research Institute; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2169-0712","authenticated-orcid":false,"given":"Steve","family":"Caritis","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynecology and Reproductive Sciences, School of Medicine, UPMC Magee-Women's Hospital;"},{"name":"Magee-Women's Research Institute; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1021-4892","authenticated-orcid":false,"given":"Imam H.","family":"Shaik","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania;"},{"name":"Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1893-3290","authenticated-orcid":false,"given":"Raman","family":"Venkataramanan","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania;"},{"name":"Magee-Women's Research Institute; and"},{"name":"Department of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"R1-20250509","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1176\/appi.ajp.2015.15020262","article-title":"Prescription opioid misuse, abuse, and treatment in the United States: an update","volume":"173","author":"Brady","year":"2016","journal-title":"Am J Psychiatry"},{"key":"R2-20250509","doi-asserted-by":"crossref","first-page":"845","DOI":"10.15585\/mmwr.mm6731a1","article-title":"Opioid use disorder documented at delivery hospitalization\u2014United States, 1999\u20132014","volume":"67","author":"Haight","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R3-20250509","doi-asserted-by":"crossref","first-page":"10481","DOI":"10.1080\/14767058.2022.2130238","article-title":"Comparison of neonatal outcomes in pregnant women undergoing medication-assisted treatment of opioid use disorder with methadone or buprenorphine\/naloxone","volume":"35","author":"Petrich","year":"2022","journal-title":"J Matern Fetal Neonatal Med."},{"key":"R4-20250509","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1056\/NEJMoa2203318","article-title":"Buprenorphine versus methadone for opioid use disorder in pregnancy","volume":"387","author":"Suarez","year":"2022","journal-title":"New Engl J Med."},{"key":"R5-20250509","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40501-020-00221-z","article-title":"Buprenorphine dosing for the treatment of opioid use disorder through pregnancy and postpartum","volume":"7","author":"Martin","year":"2020","journal-title":"Curr Treat Options Psychiatry"},{"key":"R6-20250509","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/10550887.2011.642758","article-title":"Effect of buprenorphine dose on treatment outcome","volume":"31","author":"Fareed","year":"2012","journal-title":"J Addict Dis"},{"key":"R7-20250509","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/(SICI)1098-2396(199911)34:2<83::AID-SYN1>3.0.CO;2-S","article-title":"Opioid peptide receptor studies. 12. Buprenorphine is a potent and selective mu\/kappa antagonist in the [35S]-GTP-gamma-S functional binding assay","volume":"34","author":"Romero","year":"1999","journal-title":"Synapse"},{"key":"R8-20250509","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jpsychires.2023.03.037","article-title":"The efficacy and safety of buprenorphine for the treatment of depression: a systematic review and meta-analysis","volume":"161","author":"Riblet","year":"2023","journal-title":"J Psychiatr Res."},{"key":"R9-20250509","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/01.ftd.0000197094.92559.b4","article-title":"The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry","volume":"28","author":"Huang","year":"2006","journal-title":"Ther Drug Monit."},{"key":"R10-20250509","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/FTD.0000000000000724","article-title":"Pregnancy alters CYP- and UGT-mediated metabolism of buprenorphine","volume":"42","author":"Zhang","year":"2020","journal-title":"Ther Drug Monit."},{"key":"R11-20250509","doi-asserted-by":"crossref","first-page":"64 e1","DOI":"10.1016\/j.ajog.2016.09.095","article-title":"Dose-adjusted plasma concentrations of sublingual buprenorphine are lower during than after pregnancy","volume":"216","author":"Bastian","year":"2017","journal-title":"Am J Obstetr Gynecol."},{"key":"R12-20250509","doi-asserted-by":"crossref","first-page":"459 e1","DOI":"10.1016\/j.ajog.2017.06.029","article-title":"An evidence-based recommendation to increase the dosing frequency of buprenorphine during pregnancy","volume":"217","author":"Caritis","year":"2017","journal-title":"Am J Obstet Gynecol."},{"key":"R13-20250509","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/FTD.0b013e318288453f","article-title":"Maternal hair analysis for the detection of illicit drugs, medicines, and alcohol exposure during pregnancy","volume":"35","author":"Lendoiro","year":"2013","journal-title":"Ther Drug Monit."},{"key":"R14-20250509","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cca.2006.02.019","article-title":"State of the art in hair analysis for detection of drug and alcohol abuse","volume":"370","author":"Pragst","year":"2006","journal-title":"Clin Chim Acta"},{"key":"R15-20250509","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/mas.21364","article-title":"Application of mass spectrometry to hair analysis for forensic toxicological investigations","volume":"32","author":"Vincenti","year":"2013","journal-title":"MA Spectrom Rev."},{"key":"R16-20250509","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/FTD.0000000000000693","article-title":"Monitoring prenatal exposure to buprenorphine and methadone","volume":"42","author":"Di Trana","year":"2020","journal-title":"Ther Drug Monit."},{"key":"R17-20250509","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0379-0738(03)00050-1","article-title":"Hair analysis of opiates in mothers and newborns for evaluating opiate exposure during pregnancy","volume":"133","author":"Vinner","year":"2003","journal-title":"Forensic Sci Int."},{"key":"R18-20250509","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/dta.1611","article-title":"Buprenorphine and nor-buprenorphine levels in head hair samples from former heroin users under Suboxone(R) treatment","volume":"6","author":"Belivanis","year":"2014","journal-title":"Drug Test Anal."},{"key":"R19-20250509","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1373\/clinchem.2007.091413","article-title":"Buprenorphine and norbuprenorphine in hair of pregnant women and their infants after controlled buprenorphine administration","volume":"53","author":"Goodwin","year":"2007","journal-title":"Clin Chem."},{"key":"R20-20250509","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1097\/FTD.0000000000000078","article-title":"Hair analysis for long-term monitoring of buprenorphine intake in opiate withdrawal","volume":"36","author":"Pirro","year":"2014","journal-title":"Ther Drug Monit."},{"key":"R21-20250509","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00414-011-0555-8","article-title":"Buprenorphine and norbuprenorphine findings in hair during constant maintenance dosage","volume":"125","author":"Skopp","year":"2011","journal-title":"Int J Leg Med"},{"key":"R22-20250509","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/jat\/23.4.270","article-title":"Determination of buprenorphine and norbuprenorphine in urine and hair by gas chromatography-mass spectrometry","volume":"23","author":"Vincent","year":"1999","journal-title":"J Anal Toxicol."},{"key":"R23-20250509","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/jat\/23.6.409","article-title":"A retrospective study of buprenorphine and norbuprenorphine in human hair after multiple doses","volume":"23","author":"Wilkins","year":"1999","journal-title":"J Anal Toxicol."},{"key":"R24-20250509","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/rcm.2444","article-title":"Potentials of ion trap collisional spectrometry for liquid chromatography\/electrospray ionization tandem mass spectrometry determination of buprenorphine and nor-buprenorphine in urine, blood and hair samples","volume":"20","author":"Favretto","year":"2006","journal-title":"Rapid Commun MA Spectrom."},{"key":"R25-20250509","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1520\/JFS13736J","article-title":"Hair analysis for buprenorphine and its dealkylated metabolite by RIA and confirmation by LC\/ECD","volume":"39","author":"Kintz","year":"1994","journal-title":"J Forensic Sci."},{"key":"R26-20250509","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1520\/JFS14077J","article-title":"HPLC\/MS determination of buprenorphine and norbuprenorphine in biological fluids and hair samples","volume":"42","author":"Tracqui","year":"1997","journal-title":"J Forensic Sci."},{"key":"R27-20250509","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/jat\/32.5.364","article-title":"Drug screening of hair by liquid chromatography-tandem mass spectrometry","volume":"32","author":"Hegstad","year":"2008","journal-title":"J Anal Toxicol."},{"key":"R28-20250509","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/jat\/24.6.448","article-title":"Buprenorphine to norbuprenorphine ratio in human hair","volume":"24","author":"Cirimele","year":"2000","journal-title":"J Anal Toxicol."},{"key":"R29-20250509","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.forsciint.2009.12.027","article-title":"Simultaneous screening and quantification of 52 common pharmaceuticals and drugs of abuse in hair using UPLC-TOF-MS","volume":"196","author":"Nielsen","year":"2010","journal-title":"Forensic Sci Int."},{"key":"R30-20250509","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/dta.1637","article-title":"Segmental analysis of amphetamines in hair using a sensitive UHPLC-MS\/MS method","volume":"6","author":"Jakobsson","year":"2014","journal-title":"Drug Test Anal."},{"key":"R31-20250509","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.forsciint.2011.02.015","article-title":"The role of variations in growth rate and sample collection on interpreting results of segmental analyses of hair","volume":"210","author":"LeBeau","year":"2011","journal-title":"Forensic Sci Int."},{"key":"R32-20250509","doi-asserted-by":"crossref","first-page":"e5015","DOI":"10.1002\/jms.5015","article-title":"Simplified processing and rapid quantification of buprenorphine, norbuprenorphine, and their conjugated metabolites in human plasma using UPLC-MS\/MS: assessment of buprenorphine exposure during opioid use disorder treatment","volume":"59","author":"Zhao","year":"2024","journal-title":"J MA Spectrom."},{"key":"R33-20250509","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/FTD.0b013e318228bb2a","article-title":"Preliminary buprenorphine sublingual tablet pharmacokinetic data in plasma, oral fluid, and sweat during treatment of opioid-dependent pregnant women","volume":"33","author":"Concheiro","year":"2011","journal-title":"Ther Drug Monit."},{"key":"R34-20250509","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/FTD.0b013e3181d0bd68","article-title":"Maternal buprenorphine dose, placenta buprenorphine, and metabolite concentrations and neonatal outcomes","volume":"32","author":"Concheiro","year":"2010","journal-title":"Ther Drug Monit."},{"key":"R35-20250509","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1046\/j.1360-0443.1998.93454910.x","article-title":"Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine","volume":"93","author":"Kuhlman","year":"1998","journal-title":"Addiction"},{"key":"R36-20250509","doi-asserted-by":"crossref","first-page":"686","DOI":"10.3390\/metabo11100686","article-title":"A systematic review of metabolite-to-drug ratios of pharmaceuticals in hair for forensic investigations","volume":"11","author":"Rygaard","year":"2021","journal-title":"Metabolites"},{"key":"R37-20250509","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1021\/js970360t","article-title":"Incorporation of drugs for the treatment of substance abuse into pigmented and nonpigmented hair","volume":"87","author":"Wilkins","year":"1998","journal-title":"J Pharm Sci."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001291","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T12:00:19Z","timestamp":1746792019000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001291","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"2024-03-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}